Pharmacokinetics of antofloxacin hydrochloride, a novel fluoroquinolone, after single-dose intravenous administration in healthy Chinese male volunteers

Xenobiotica

Volumn 40, Issue 5, 2010, Pages 344-349

  Wang, J ^a   Xiao, Y ^a   Lu, Y ^a   Kang, Z ^a   Zhang, M ^a   Liu, Y ^a   Liang, J ^a   Li, T ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Antofloxacin hydrochloride; Healthy Chinese male volunteers; Intravenous dose; Pharmacokinetics; Serum; Single

Indexed keywords

ANTOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; OFLOXACIN; QUINOLONE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION; VOLUNTEER; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY; CHINA; DOSE RESPONSE; HEALTH; INTRAVENOUS DRUG ADMINISTRATION; TIME; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HEALTH; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OFLOXACIN; TIME FACTORS; YOUNG ADULT;

EID: 77950819937     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003649798     Document Type: Article

References (14)

1. Hu JH, Xie L, Liu XD. (2006). Determination of antofloxacin in rat plasma and bile by HPLC and study of its pharmacokinetics. J Chin Pharmaceut Uni 37(2):153-156
2. Kaitin KI. (1998). Global drug development and international harmonization: the emergence of China as a world pharmaceutical player. Drug Inform J 32:1187S-91S.
3. Li CJ, Chen DY, Chen KX. (2004). Current status of drug discovery and development in China. Chin Bull Life Sci 16(5):324-329
4. Liang Y, Liu L, Lu SS, Xie L, Kang A, Xie T, Xie Y, Sheng LS, Liu XD, Wang GJ. (2009). Application of a hybrid ion trap/time-of-flight mass spectrometer in metabolite characterization studies: structural identification of the metabolism profile of antofloxacin in rats rapidly using MSn information and accurate mass measurements. J Pharmaceut Biomed Anal 50:1022-1025
5. Lin HY, Shen HL. (2006). Antibiotics clinical usage in general hospital. Chin J Nosocomiol 16(6):681-683
6. Lode H, Burner K, Keppel P. (1998). Pharmacodynamics of fluoroquinolones. Clin Infect Dis 27:33-39
7. Meibohm B, Derendore H. (2002). Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharmaceut Sci 91:18-31.
8. Sun YY, Cai H, Tu CH. (2007). A comparative study on juvenile rat knee joint cartilage toxicity of levofloxacin and antofloxacin after intragastric administration. J Toxicol (Chinese) 21(4):293-294
9. Xiao XM, Xiao YH. (2008). Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection. Acta Pharmacol Sin 29(10):1253-1260
10. Xiao YH, Lu Y, Kang ZS, Hou F, Wang S, Li TY, Liu Y, Xia YH. (2008a). Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Ther 46(4):172-179 (Pubitemid 351493987)
11. Xiao YH, Lu Y, Kang ZS, Zhang M, Liu Y, Li TY. (2008b). Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Disposit 29(3):167-172 (Pubitemid 351722161)
12. Yang C, Yuan Z, Huang WX, Liu CW. (2009). A randomized controlled, double-blind and double-stimulation clinical trial of antofloxacin hydrochloride and verse levofloxacin hydrochloride for the treatment of acute respiratory infections. Chin J Antibiot 34(5):316-319
13. Yu H, Wu JM, Yang YS, Chen KX, Ji RY. (2002). Antibacterial activities of the derivatives YH54 and YH57 of levofloxacin in vitro. Chin Pharmacol Bull 18(1):112-113
14. Zhu Q, Liao J, Xie L, Wang GJ, Liu XD. (2009). Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 39(4):293-301.